Bicocca Open Archive

Logo unimib boa
ZAMBELLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.262
EU - Europa 574
AS - Asia 447
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 2.289
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.238
SG - Singapore 157
CN - Cina 123
DE - Germania 119
IT - Italia 115
SE - Svezia 79
IE - Irlanda 75
ID - Indonesia 67
RU - Federazione Russa 64
HK - Hong Kong 46
UA - Ucraina 35
VN - Vietnam 33
GB - Regno Unito 27
CA - Canada 24
AT - Austria 23
TR - Turchia 13
FI - Finlandia 11
FR - Francia 9
DK - Danimarca 8
NL - Olanda 5
EU - Europa 3
IR - Iran 3
BE - Belgio 2
IN - India 2
PH - Filippine 2
BR - Brasile 1
CZ - Repubblica Ceca 1
KZ - Kazakistan 1
MA - Marocco 1
NZ - Nuova Zelanda 1
RO - Romania 1
Totale 2.289
Salva come PNG Salva come JPEG
Città #
Ann Arbor 258
Singapore 129
Fairfield 126
Woodbridge 107
Chandler 94
Dublin 74
Frankfurt am Main 74
Jakarta 67
Seattle 67
Wilmington 60
Ashburn 57
Houston 53
Hong Kong 46
Dearborn 38
Cambridge 36
Jacksonville 36
Milan 35
Santa Clara 33
Princeton 30
New York 29
Nuremberg 24
Dong Ket 21
Shanghai 21
Altamura 15
Lawrence 14
Vienna 13
Guangzhou 11
Kocaeli 11
Nanjing 10
Lissone 9
Ottawa 9
San Diego 9
Boardman 8
Wuxi 8
Arezzo 7
Lachine 7
Gainesville 6
Hangzhou 6
Shenzhen 6
Columbus 5
Hebei 5
Toronto 5
Andover 4
Helsinki 4
Moscow 4
Shenyang 4
Changsha 3
Chicago 3
Jiaxing 3
Jinan 3
London 3
Tianjin 3
Amsterdam 2
Beijing 2
Bologna 2
Brussels 2
Casalecchio di Reno 2
Edmonton 2
Kiev 2
Mountain View 2
Munich 2
Pavia 2
Taizhou 2
Verona 2
Zanjan 2
Zhengzhou 2
Almaty 1
Almere Stad 1
Auckland 1
Azzano 1
Belfast 1
Bremen 1
Brno 1
Busto Arsizio 1
Chengdu 1
Clearwater 1
Dallas 1
Falkenstein 1
Falls Church 1
Haikou 1
Henderson 1
Hillsborough 1
Hounslow 1
Islington 1
Kashan 1
Kingston 1
Kunming 1
Lanzhou 1
Las Vegas 1
Laurel 1
Leawood 1
Leesburg 1
Loreto 1
Mola Di Bari 1
Nanchang 1
Nanyang 1
New Bedfont 1
Newark 1
Ningbo 1
Norwalk 1
Totale 1.775
Salva come PNG Salva come JPEG
Nome #
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival 228
Management and Survival of Pleural Mesothelioma: A Record Linkage Study 215
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 207
Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study 166
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. 165
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 164
Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study 156
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 138
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 116
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 114
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 111
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 71
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 69
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 48
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 45
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 28
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 19
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 19
Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study 16
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 16
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 16
International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality 15
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 14
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 12
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 12
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment 11
COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry 10
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds 10
Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence 9
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 9
Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis 9
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 9
Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies 8
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 8
The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy 8
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 7
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer 7
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients 7
Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool 7
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 7
Clinical Review on the Management of Breast Cancer Visceral Crisis 7
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 7
The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question 7
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy 7
Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives 7
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer - Immun-HER trial (GOIRC-01-2016) 6
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 6
Evolving phenotypes of non-hospitalized patients that indicate long COVID 6
A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial 6
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 6
Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study 6
Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations 6
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium 6
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 6
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy 6
Potential Role of Circulating miRNAs for Breast Cancer Management in the Neoadjuvant Setting: A Road to Pave 6
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 6
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 6
Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer 6
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score 6
What Every Reader Should Know About Studies Using Electronic Health Record Data but May Be Afraid to Ask 6
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 6
Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium 6
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis 6
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets 6
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer 6
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer 5
i2b2 to optimize patients enrollment 5
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 5
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 5
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 5
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 5
BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork 5
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants 5
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 5
Potential pitfalls in the use of real-world data for studying long COVID 5
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 5
Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527](S1040842824002701)(10.1016/j.critrevonc.2024.104527) 5
Correction to: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors (Journal of Endocrinological Investigation, (2023), 47, 2, (433-442), 10.1007/s40618-023-02174-5) 5
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 5
The "Hub and Spoke" model has no effect on mortality in acute upper gastrointestinal bleeding: A prospective multicenter cohort study 5
Erratum: Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants (Genetics in Medicine (2022) 24(1) (119–129), (S1098360021011308), (10.1016/j.gim.2021.08.016)) 5
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 5
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy 5
Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper 5
The central role of pathology labs in breast cancer precision oncology: a call for action 4
Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer 4
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 4
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 4
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors 4
The interaction of patients’ physical status and time to endoscopy on mortality risk in patients with upper gastrointestinal bleeding: A national prospective cohort study 4
Opportunities and Challenges of Synthetic Data Generation in Oncology 4
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 4
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study 4
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems 4
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry 4
Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care 4
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 4
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic 4
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 4
Totale 2.622
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.685
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.685
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020165 0 0 0 0 0 0 41 29 38 22 23 12
2020/2021368 11 27 29 32 23 22 18 37 35 49 21 64
2021/2022201 17 23 36 12 4 13 5 8 8 21 25 29
2022/2023357 35 123 36 22 22 49 0 22 22 1 15 10
2023/2024213 5 6 11 8 32 50 42 8 19 0 7 25
2024/2025860 31 74 15 28 60 646 6 0 0 0 0 0
Totale 2.678